Dihydrotestosterone
Research stageAlso known as (5-alpha, 17-beta)-17-hydroxyandrostan-3-one, 17beta-Hydroxy-5alpha-androstan-3-one, 17beta-Hydroxy-5alpha-androstane-3-one, 17beta-Hydroxyandrostan-3-one+11 more
(5-alpha, 17-beta)-17-hydroxyandrostan-3-one, 17beta-Hydroxy-5alpha-androstan-3-one, 17beta-Hydroxy-5alpha-androstane-3-one, 17beta-Hydroxyandrostan-3-one, 4-Dihydrotestosterone, 5-alpha-dihydrotestosterone, 5alpha-Dihydrotestosterone, Androstanolona, Androstanolone, Androstanolonum, DHT, DHT - 5-alpha-dihydrotestosterone, Stanolone, Dihydrotestosteron, Dihydrotestostérone.
Recent clinical, regulatory, research and industry developments relating to this drug.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Annals of internal medicine1
- Frontiers in endocrinology1
- Adams RJ1
- Adamski J1
- Antonio L1
- Ballantyne CM1
- Banerjee R1
- Bauer DC1
- Bhasin S1
- Biggs ML1
- Adelaide Institute for Sleep Health1
- ANZAC Research Institute1
- Australian Institute of Family Studies1
- Baylor College of Medicine1
- Brigham and Women's Hospital1
- Centre for Big Data Research in Health1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across the same disease area as Dihydrotestosterone in the shared literature.
Studied across the same disease area as Dihydrotestosterone in the shared literature.
Studied across the same disease area as Dihydrotestosterone in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature